Ken Research Logo

Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:Europe

Product Code:GDPH58321D

Published On

November 2018

Total pages

48

About the Report

Summary

Active Biotech AB (Active Biotech) is a biotechnology company that develops and commercializes pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company's key products in development include Laquinimod (neurodegenerative diseases); Anyara (cancer); Tasquinimod (cancer); Paquinimod (Systemic Sclerosis); and SILC (autoimmune diseases). It has licensing agreements with Teva Pharmaceutical Industries, NeoTX, Ipsen, Teva Neuroscience and MediGene AG. Active Biotech is headquartered in Lund, Sweden.

Active Biotech AB (ACTI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Scope of the Report

Products

Active Biotech AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Active Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Active Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Active Biotech AB, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

NeoTX Therapeutics Enters into Licensing Agreement with Active Biotech 11

Equity Offering 12

Active Biotech Raise USD6 Million in Right Offering of Shares 12

Active Biotech Raises USD6.1 Million in Rights Offering of Shares 13

Active Biotech to Raise USD30.4 Million in Rights Offering of Shares 14

Active Biotech Completes Private Placement Of Shares For USD 42 Million 15

Active Biotech AB-Key Competitors 16

Active Biotech AB-Key Employees 17

Active Biotech AB-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Strategy And Business Planning 19

Sep 07, 2018: Teva returns laquinimod global rights to Active Biotech 19

Financial Announcements 20

Aug 09, 2018: Active Biotech-interim report January-June 2018 20

May 17, 2018: Active Biotech: Interim report January-March 2018 24

Nov 09, 2017: Active Biotech AB-Interim report January-September 2017 28

Aug 10, 2017: Active Biotech: Interim report January-June 2017 29

Apr 27, 2017: Active Biotech: Interim Report January-March 2017 31

Feb 16, 2017: Active Biotech Year-end report January-December 2016 34

Corporate Communications 38

Jun 19, 2017: Helen Tuvesson new CEO of Active Biotech from July 1, 2017 38

Product News 39

10/19/2017: Teva to Highlight New Data on Laquinimod at Joint ECTRIMS-ACTRIMS Congress in Paris 39

05/05/2017: Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint 40

04/19/2017: Teva Pharmaceutical to Present Data on Laquinimod at 69th Annual Meeting of the American Academy of Neurology 41

04/17/2018: Teva to Present laquinimod sodium at 70th Annual Meeting of the American Academy of Neurology 42

Clinical Trials 43

Aug 01, 2018: Teva reports negative data from LEGATO-HD trial 43

Dec 01, 2017: Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS 44

Other Significant Developments 45

Feb 15, 2018: Active Biotech: Year-end report January-December 2017 45

Dec 20, 2017: Active Biotech provides updated information about the company's financial position 46

Dec 07, 2017: Active Biotech provides updated information about the company's financial position-the company currently lacks funding to ensure its operations for the coming twelve-month period 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

Research Methodology

Why Buy From Us?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022